Efficacy and safety of parecoxib sodium for acute postoperative pain: A meta-analysis

Wei,Wei; Zhao,Tianyun; Li,Yuantao

doi:10.3892/etm.2013.1172

Efficacy and safety of parecoxib sodium for acute postoperative pain: A meta-analysis

Authors:
- Wei Wei
- Tianyun Zhao
- Yuantao Li
View Affiliations

Affiliations: Department of Anesthesiology, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China, Department of Anesthesiology, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong 518028, P.R. China
Published online on: June 20, 2013 https://doi.org/10.3892/etm.2013.1172
Pages: 525-531

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This meta-analysis was performed to evaluate the efficacy and safety of parecoxib sodium for acute postoperative pain. PubMed, Cochrane Central Register of Controlled Trials, EBSCO, Springer, Ovid and Chinese National Knowledge Infrastructure (CNKI) databases were searched from January 1999 to January 2013 to comprehensively collect randomized controlled trials (RCTs) of parecoxib sodium for acute postoperative pain. The methodological quality of the included RCTs were assessed and the data were extracted by two reviewers independently according to the Cochrane Handbook. Efficacies and safety (respiratory depression, pruritus, fever, headache, and nausea and vomiting) were pooled using meta‑analysis performed by Review Manager 5.1 software. Relative risk (RR) and 95% confidence interval (CI) were calculated in a fixed-effects model. Seven RCTs involving 1,939 patients met the inclusion criteria. The results of the meta‑analysis revealed that the rate of ‘effective’ treatment as described by the patients' global evaluation of study medication (PGESM) was higher in the patient-controlled analgesia (PCA) combined with parecoxib sodium group 24, 48, and 72 h after the initial intravenous dose of 40 mg parecoxib compared with that in the control group [PCA alone; RR=1.41, 95% CI (1.13-1.75); RR=1.25, 95% CI (1.15-1.35); and RR=1.30, 95% CI (1.21‑1.40), respectively]. The rate of ‘ineffective’ treatment in the PCA combined with parecoxib sodium group was lower compared with that of the control group [RR=0.43, 95% CI (0.26-0.72); RR=0.44, 95% CI (0.34‑0.57); and RR=0.33, 95% CI (0.23-0.48), respectively]. Combination of PCA with parecoxib sodium reduced the incidence of postoperative fever [RR=0.34, 95% CI (0.22-0.53)], as well as nausea and vomiting [RR=0.69, 95% CI (0.57-0.83)]; however, it did not significantly reduce respiratory depression [RR=0.84, 95% CI (0.38-1.83)], pruritus [RR=0.91, 95% CI (0.54-1.52)] or headache [RR=0.77, 95% CI (0.47-1.28)]. The combination of PCA with parecoxib sodium successively injected for <3 days significantly increases the scores of PGESM and reduces the incidence of adverse effects and postoperative complications.

View Figures

View References

1.	Barden J, Derry S, McQuay HJ and Moore RA: Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 4:CD0073552009.PubMed/NCBI
2.	Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nat New Biol. 231:232–235. 1971. View Article : Google Scholar : PubMed/NCBI
3.	Needleman P and Isakson PC: The discovery and function of COX-2. J Rheumatol Suppl. 49:6–8. 1997.
4.	Rømsing J and Møiniche S: A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand. 48:525–546. 2004.PubMed/NCBI
5.	Lloyd R, Derry S, Moore RA and McQuay HJ: Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2:CD0047712009.PubMed/NCBI
6.	Graff J, Arabmotlagh M, Cheung R, Geisslinger G and Harder S: Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study. Clin Ther. 29:438–447. 2007. View Article : Google Scholar
7.	Harris SI, Stoltz RR, LeComte D and Hubbard RC: Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects. J Clin Gastroenterol. 38:575–580. 2004. View Article : Google Scholar
8.	Noveck RJ, Laurent A, Kuss M, Talwalker S and Hubbard RC: Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomised, controlled trials. Clin Drug Investig. 21:465–476. 2001. View Article : Google Scholar
9.	Stoltz RR, Harris SI, Kuss ME, LeComte D, Talwalker S, Dhadda S and Hubbard RC: Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol. 97:65–71. 2002. View Article : Google Scholar
10.	Sackett DL, Clarke M and Oxman AD: Cochrane Reviewers, Handbook 4.2. Renew Manager. Versions 4.2 Oxford, England: The cochrane collaboration; pp. 13–36. 2002
11.	Jüni P, Altman DG and Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 323:42–46. 2001.
12.	Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
13.	Jüni P and Egger M: PRISMAtic reporting of systematic reviews and meta-analyses. Lancet. 374:1221–1223. 2009.
14.	Apfelbaum JL, Desjardins PJ, Brown MT and Verburg KM: Multiple-day efficacy of parecoxib sodium treatment in postoperative bunionectomy pain. Clin J Pain. 24:784–792. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Michael C, Artur J, Kotarski J, Katz TK, Brown MT and Verburg KM: Parecoxib sodium administered over several days reduces pain after gynecologic surgery via laparotomy. J Clin Anesth. 19:448–455. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Viscusi ER, Gimbel JS, Halder AM, Snabes M, Brown MT and Verburg KM: A multiple-day regimen of parecoxib sodium 20 mg twice daily provides pain relief after total hip arthroplasty. Anesth Analg. 107:652–660. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Tang J, Li S, White PF, Chen X, Wender RH, Quon R, Sloninsky A, Naruse R, Kariger R, Webb T and Norel E: Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology. 96:1305–1309. 2002. View Article : Google Scholar : PubMed/NCBI
18.	Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L and Hubbard RC: Parecoxib sodium, a parenteral cyclooxygenase-selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology. 98:950–957. 2003. View Article : Google Scholar
19.	Jirarattanaphochai K, Thienthong S, Sriraj W, Jung S, Pulnitiporn A, Lertsinudom S and Foocharoen T: Effect of parecoxib on postoperative pain after lumbar spine surgery. Spine. 33:132–139. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Hubbard RC, Naumann TM, Traylor L and Dhadda S: Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth. 90:166–172. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Koppert W, Wehrfritz A, Körber N, Sittl R, Albrecht S, Schüttler J and Schmelz M: The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. 108:148–153. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Beaulieu P: Non-opioid strategies for acute pain management. Can J Anaesth. 54:481–485. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Maund E, McDaid C, Rice S, Wright K, Jenkins B and Woolacott N: Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth. 106:292–297. 2011. View Article : Google Scholar
24.	Higgins J, Thompson S, Deeks J and Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 7:51–61. 2002. View Article : Google Scholar : PubMed/NCBI